MDX-210 bispecific antibody targeting the HER-2 cancer marker and the Fc receptor on immune cells data

MEDX presented data on its Phase I/II trial in breast cancer patients, showing clinical improvement in one of eight patients, and a stimulation of immune response at all dose levels tested. At a confe...